REFERENCES
- Grant B F, Stinson F S, Dawson D A, Chou S P, Dufour M C, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Arch Gen Psychiatry 2004; 61: 807–816
- Kessler R C, Nelson C B, McGonagle K A, Edlund M J, Frank R G, Leaf P J. The epidemiology of co-occurring addictive and mental disorders. Am J Orthopsychiatry 1996; 66: 17–31
- Goetzel R Z, Hawkins K, Ozminkowski R J. The health and productivity cost burden of the “top 10” physical and mental conditions affecting six large US employers in 1999. J Occup Environ Med 2003; 45: 5–14
- Hirschfield R, Hasin D, Keller M, Endicott J, Wunder J. Depression and alcoholism: Comorbidity in a longitudinal study. Comorbidity of Mood and Anxiety Disorders, J Maser, C Cloninger. American Psychiatric Press, Washington, DC 1990; 293–304
- Merikangas K, Stevens D E. Substance abuse among women: familial factors and comorbidity. Drug Addiction Research and Health of Women, C L Wetherington, A B Roman. National Institute on Drug Abuse, Bethesda, Md 1998; 245–269
- Schuckit M A. Drug and alcohol abuse: A clinical guide to diagnosis and treatment, 6th ed. Springer, New York 2006
- Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. The characteristics of heroin users entering treatment: Findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005; 24(5)411–418
- Ahmadi J, Toobaee S, Kharras M. Psychiatric disorders in opioid dependents. Int J Soc Psychiatry 2003; 49(3)185–191
- Schuckit M A. Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006; 101: 76–88
- Patten S B, Lamarre C J. Can drug-induced depressions be identified by their clinical features?. Can J Psychiatry 1992; 37: 213–215
- Sullivan M D, Edlund M J, Steffick D, Unützer J. Regular use of prescribed opioids: Association with common psychiatric disorders. Pain 2005; 15: 95–103, 119(1–3)
- Montgomery S A. Is there a role for a pure noradrenergic drug in the treatment of depression?. Eur Neuropsychopharmacol 1997; 7: 3–9
- Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997; 11: 25–31
- Montgomery S A. The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 1989; 4: 113–119
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
- Beck A T, Weissman A, Lester D, Trexler L. The measurement of pessimism: The hopelessness scale. J Consult Clin Psychol 1974; 6: 861–865
- Davis L L, Frazier E, Husain M M, Warden D, Trivedi M, Fava M, et al. Substance use disorder comorbidity in major depressive disorder: A confirmatory analysis of the STAR*D cohort. Am J Addict 2006; 15(4)278–285
- Davis L L, Rush J A, Wisniewski S R, Rice K, Cassano P, Jewell M E, et al. Substance use disorder comorbidity in major depressive disorder: An exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort. Compr Psychiatry 2005; 46(2)81–9; 570